Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial.

Bhadri V, Gelderblom H, Stacchiotti S, Bauer S, Wagner AJ, van de Sande M, Bernthal NM, López Pousa A, Abdul Razak A, Italiano A, Ahmed M, Le Cesne A, Tinoco G, Boye K, Martín-Broto J, Palmerini E, Tafuto S, Pratap S, Powers BC, Reichardt P, Casado Herráez A, Rutkowski P, Tait C, Agnello G, Harrow B, Saunders A, Sharma MG, Sherman ML, Blay JY, Tap WD

Open source

DOI: 10.1093/oncolo/oyag421
Published: 2026 Oct 7
Container: The oncologist
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyag421,
  title = {Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial.},
  author = {Bhadri V and Gelderblom H and Stacchiotti S and Bauer S and Wagner AJ and van de Sande M and Bernthal NM and López Pousa A and Abdul Razak A and Italiano A and Ahmed M and Le Cesne A and Tinoco G and Boye K and Martín-Broto J and Palmerini E and Tafuto S and Pratap S and Powers BC and Reichardt P and Casado Herráez A and Rutkowski P and Tait C and Agnello G and Harrow B and Saunders A and Sharma MG and Sherman ML and Blay JY and Tap WD},
  year = {2026},
  journal = {The oncologist},
  doi = {10.1093/oncolo/oyag421},
  url = {https://doi.org/10.1093/oncolo/oyag421}
}

RIS

TY  - JOUR
TI  - Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial.
AU  - Bhadri V
AU  - Gelderblom H
AU  - Stacchiotti S
AU  - Bauer S
AU  - Wagner AJ
AU  - van de Sande M
AU  - Bernthal NM
AU  - López Pousa A
AU  - Abdul Razak A
AU  - Italiano A
AU  - Ahmed M
AU  - Le Cesne A
AU  - Tinoco G
AU  - Boye K
AU  - Martín-Broto J
AU  - Palmerini E
AU  - Tafuto S
AU  - Pratap S
AU  - Powers BC
AU  - Reichardt P
AU  - Casado Herráez A
AU  - Rutkowski P
AU  - Tait C
AU  - Agnello G
AU  - Harrow B
AU  - Saunders A
AU  - Sharma MG
AU  - Sherman ML
AU  - Blay JY
AU  - Tap WD
PY  - 2026
JO  - The oncologist
DO  - 10.1093/oncolo/oyag421
UR  - https://doi.org/10.1093/oncolo/oyag421
ER  -

APA

V, B., H, G., S, S., S, B., AJ, W., M, V. D. S., NM, B., A, L. P., A, A. R., A, I., M, A., A, L. C., G, T., K, B., J, M., E, P., S, T., S, P., BC, P., P, R., A, C. H., P, R., C, T., G, A., B, H., A, S., MG, S., ML, S., JY, B., & WD, T. (2026). Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial.. The oncologist. https://doi.org/10.1093/oncolo/oyag421

Source records

pubmed · retrieved 2026-11-10T11:21:57.200Z